Carrier-free single-molecule hypoxia-activated nanoprodrug of SN38 with ultrahigh drug loading for pancreatic cancer treatment.
1/5 보강
Pancreatic cancer remains one of the most lethal malignancies for human health.
APA
Regmi A, Elayyan M, et al. (2025). Carrier-free single-molecule hypoxia-activated nanoprodrug of SN38 with ultrahigh drug loading for pancreatic cancer treatment.. Journal of materials chemistry. B, 13(44), 14416-14424. https://doi.org/10.1039/d5tb01434d
MLA
Regmi A, et al.. "Carrier-free single-molecule hypoxia-activated nanoprodrug of SN38 with ultrahigh drug loading for pancreatic cancer treatment.." Journal of materials chemistry. B, vol. 13, no. 44, 2025, pp. 14416-14424.
PMID
41091112 ↗
Abstract 한글 요약
Pancreatic cancer remains one of the most lethal malignancies for human health. The anticancer drug SN38 has been proven effective against pancreatic cancer cells; however, its clinical application is limited by its poor aqueous solubility and restricted bioavailability . In this work, we developed a novel carrier-free single-molecule hypoxia-responsive nanoprodrug of SN38 for the treatment of pancreatic tumors. The nanoprodrug has an ultrahigh drug-loading content of ∼80 wt% and a nanoscale size of ∼50 nm. The drug molecules are masked by a hypoxia-sensitive aromatic azo group in the nanoprodrug, thereby shielding the therapeutic effects and toxicities of SN38 under normoxic conditions. Thus, the toxicity of the new regimen toward healthy cells and tissues is alleviated. In response to the upregulated level of azoreductase enzymes in the hypoxic tumor microenvironment, SN38 molecules are released with their intact structures, exerting a powerful suppressive effect on tumor cells.
🏷️ 키워드 / MeSH 📖 같은 키워드 OA만
🏷️ 같은 키워드 · 무료전문 — 이 논문 MeSH/keyword 기반
- A Phase I Study of Hydroxychloroquine and Suba-Itraconazole in Men with Biochemical Relapse of Prostate Cancer (HITMAN-PC): Dose Escalation Results.
- Self-management of male urinary symptoms: qualitative findings from a primary care trial.
- Clinical and Liquid Biomarkers of 20-Year Prostate Cancer Risk in Men Aged 45 to 70 Years.
- Diagnostic accuracy of Ga-PSMA PET/CT versus multiparametric MRI for preoperative pelvic invasion in the patients with prostate cancer.
- Clinical Presentation and Outcomes of Patients Undergoing Surgery for Thyroid Cancer.
- Association of patient health education with the postoperative health related quality of life in low- intermediate recurrence risk differentiated thyroid cancer patients.